pemvidutide
·Code: ALT-801
pemvidutide: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Altimmune, Inc. (ALT) | Phase 2 |
Clinical Trials (1)
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
FDA Decisions
FDA_MeetingFDA indicated openness to incorporating AIM-MASH AI Assist and receptive to evaluating multiple doses including 2.4 mg; final minutes expected Jan 2026.(ALT)
Frequently asked questions
Who is developing pemvidutide?
pemvidutide is being developed by Altimmune, Inc..
How many clinical trials involve pemvidutide?
BioSniper tracks 1 clinical trial involving pemvidutide.
What is pemvidutide's latest FDA decision?
The most recent tracked FDA decision for pemvidutide is FDA_Meeting for FDA indicated openness to incorporating AIM-MASH AI Assist and receptive to evaluating multiple doses including 2.4 mg; final minutes expected Jan 2026., dated December 11, 2025.
Get deeper analysis on pemvidutide
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis